NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
16/06/2026
Voltar para busca
Dado oficial do USPTO
4C PHARMA SOLUTIONS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
4C PHARMA SOLUTIONS
ST13
US500000088232337Classe
35, 41, 42, 44, 45
Pedido
88232337
Registro
5849323
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
17/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 41, 42, 44, 45
Data de depósito
17/12/2018
Data de registro
03/09/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2026
Última transação
17/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Primeiro uso
08/09/2018
Primeiro uso no comércio
08/09/2018
Código do desenho
4
Tipo de titular
16
Localização do titular
Piscataway, NJ, US
Examinador
WILKE, JOHN
Localização atual
Historical data usage
Titulares e representantes
Titulares
4C Pharma Solutions LLC
Representantes
ESTEBAN O'FARRELL
Classificação técnica
Classes Nice
Classe 35Classe 41Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Regulatory submission managementassisting others in preparing and filing applications for new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics with governmental regulatory bodies; business consulting and management in the field of clinical trialsclinical data and regulatory submission management on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical researchclinical trials and applications for new druggeneric drugmedical devicedrug/device combinationbiologicbiosimilarnutraceuticalconsumer product or cosmetic approval; regulatory submission managementassisting others in preparing and filing applications for new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics with governmental regulatory bodies; providing consulting services in the field of regulatory submission management to companies to assist them with applications for new druggeneric drugmedical devicedrug/device combinationbiologicbiosimilarnutraceuticalconsumer product or cosmetic approval; interactive record-keeping services for use in risk management and regulatory compliance by insurers and professionals in the medical field; business risk assessment services
Classe 41
Training services in the field of pharmacovigilance and regulatory compliance
Classe 42
Technical writing for others; technical writing in the field of medical writing; searching and retrieving informationsitesother resources available on computer networks for others; consulting services for others in the field of designplanningimplementation project management of clinical trials and pharmacovigilance; installation and maintenance of pharmacovigilance computer software; tracking and monitoring of safety and/or efficacy for drugsdevicesdrug/device combinationsbiologicsbiosimilarscosmeticsnutraceuticals or consumer products for others for pharmacovigilance purposes
Classe 44
Providing medical information in the field of pharmacovigilance and clinical trials
Classe 45
Regulatory compliance consulting in the field of prescription drug sampling; tracking and monitoring regulatory requirements in the field of new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics for regulatory compliance purposes; regulatory compliance consulting in the field of new drugsgeneric drugsmedical devicesdrug/device combinationsbiologicsbiosimilarsnutraceuticalsconsumer products or cosmetics
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
16/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/06/2026
ES8R
TEAS SECTION 8 RECEIVED
02/03/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/02/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/02/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/02/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/02/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/02/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/09/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/06/2019
PUBO
PUBLISHED FOR OPPOSITION
18/06/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/05/2019
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
15/05/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
10/05/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/05/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/05/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/05/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
03/05/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/05/2019
ZZAX
PREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU
03/05/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/05/2019
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
23/04/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/04/2019
ALIE
ASSIGNED TO LIE
10/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/03/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
18/03/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/03/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
18/03/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/03/2019
DOCK
ASSIGNED TO EXAMINER
13/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/01/2019
NWAP
NEW APPLICATION ENTERED
20/12/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace 4C PHARMA SOLUTIONS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.